Gleevec Related Clinical Trials
A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) [Active, not recruiting]
Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma [Terminated]
Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma [Active, not recruiting]
Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia [Completed]
Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer [Active, not recruiting]
Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients [Completed]
Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma [Active, not recruiting]
Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. [Recruiting]
Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate [Completed]
Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer [Completed]
Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer [Recruiting]
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent MG [Recruiting]
Effect of Antacids on Gleevec® in Healthy Volunteers [Completed]
Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) [Recruiting]
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) [Recruiting]
Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy. [Active, not recruiting]
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients [Recruiting]
Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer [Recruiting]
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) [Active, not recruiting]
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma [Recruiting]
Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia [Active, not recruiting]
Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma [Recruiting]
Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas [Recruiting]
Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC [Terminated]
CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML) [Recruiting]
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator [Not yet recruiting]
Effect of Calcium on Gleevec Pharmacokinetics (PK) in Healthy Volunteers [Recruiting]
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer [Active, not recruiting]
New Individualized Therapy Trial for Metastatic Colorectal Cancer [Recruiting]
Randomized ph Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib [Recruiting]
Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC) [Recruiting]
Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [Recruiting]
A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients [Recruiting]
Ipilimumab and Imatinib Mesylate in Advanced Cancer [Not yet recruiting]
Imatinib Mesylate (Glivec) as Maintenance Therapy After Cytogenetic Response With Nilotinib (AMN107, Tasigna) First Line in Newly Diagnosed Chronic Myelogenous Leukemia [Recruiting]
A Global Imatinib and Nilotinib Pregnancy Exposure Registry [Recruiting]
Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia [Recruiting]
Efficacy and Safety of Imatinib in Scleroderma [Recruiting]
Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia [Recruiting]
Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib [Recruiting]
Imatinib Mesylate (Gleevec; STI571) in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed by Surgery [Active, not recruiting]
Rechallenge of Imatinib in GIST Having no Effective Treatment [Recruiting]
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes [Recruiting]
Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus [Not yet recruiting]
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST [Recruiting]
Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children [Recruiting]
Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis [Recruiting]
Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma [Recruiting]
Therapy of Early Chronic Phase CML With Gleevec
Safety Study of Gleevec® in Children With Pulmonary Hypertension [Recruiting]
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes [Completed]
Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day) [Completed]
Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML. [Recruiting]
Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib [Completed]
Imatinib in KIT-negative Systemic Mastocytosis [Recruiting]
Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST) [Completed]
A Study of Imatinib 400 Mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis. [Completed]
Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor [Recruiting]
Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease [Recruiting]
Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA) [Recruiting]
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP [Completed]
Glivec Phase II Pediatric Study [Terminated]
Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase [Recruiting]
Phase IIb Study of Dasatinib Versus Imatinib in Patients With CML-CP Who Have Not Achieved an Early Optimal Response to Imatinib [Recruiting]
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec) [Completed]
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec) [Completed]
Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia [Completed]
Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec) [Completed]
Oblimersen Plus Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia [Active, not recruiting]
Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma [Active, not recruiting]
Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C [No longer recruiting]
Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer [Recruiting]
Imatinib Mesylate in Treating Patients With Myelofibrosis [Active, not recruiting]
BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate [No longer recruiting]
Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia [Active, not recruiting]
Imatinib in Dermatofibrosarcoma Protuberans (DFSP) [Active, not recruiting]
AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevecâ„¢ [Terminated]
Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors [Recruiting]
Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer [Completed]
Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer [Completed]
Imatinib Mesylate in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia [Recruiting]
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia [No longer recruiting]
Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia [Completed]
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [Completed]
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor [No longer recruiting]
Effect of Food on Bioavailability of Modified Release Formulations of Imatinib [Active, not recruiting]
Imatinib Mesylate in Treating Patients With Metastatic Melanoma [Suspended]
Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer [Completed]
Adjuvant Imatinib in High-Risk GIST With c-Kit Mutation [Recruiting]
Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Carcinosarcoma [No longer recruiting]
Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer [Completed]
Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor [No longer recruiting]
Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia [No longer recruiting]
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases [Completed]
Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response [Not yet recruiting]
Study of BMS-354825 in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib [Completed]
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma [No longer recruiting]
Role of Glivec in Patients With Tumor Cells Positive for c-Kit or PDGFR; a Multi Center Study. [No longer recruiting]
|
